survodutide calculator
10 mg in 2 mL = 5 mg/mL; 10 units on a U-100 syringe holds 0.5 mg.
Sizes on sale: 6mg, 10mg. Choose a vial, the water and the amount per draw; prices are the lowest current US offers.
price, vial size and certificate correction
Most 2–15 mg vials hold 3 mL.
From the lot certificate; it replaces the label amount.
5 mg/mL
10 units holds 0.5 mg
- concentration
- 5 mg/mL
- per unit
- 50 mcg per unit
- full draws per vial
- —
- cost per draw
- —
the working
- 10 mg ÷ 2 mL = 5 mg/mL
If this is a prescription, the dose and volume on your pharmacy label take priority. Ask your pharmacist about any mismatch.
human trials · cited sources
doses of Survodutide used in research
Investigational glucagon/GLP-1 dual agonist with no approval found as of 2026-11-04; phase 3 SYNCHRONIZE-1 (NEJM 2026) used doses adjusted up to 3.6 mg or 6.0 mg once weekly for 76 weeks. These are the amounts specific labels and studies used, linked to each source. They are references, not recommendations; a prescription label takes priority.
| source | who | amount and schedule | route |
|---|---|---|---|
| Phase 3 SYNCHRONIZE-1 (NEJM 2026): up to 6.0 mg weekly for 76 weeks phase 3 trial · 2026 · PMID 42253238 | 725 adults with BMI 30 or higher (or 27 or higher with an obesity-related complication), without diabetes | 6 mg once weekly 76 weeks Arms were dose-adjusted up to 3.6 mg or up to 6.0 mg weekly; the escalation steps are not given in the abstract or registry. Mean weight change at week 76 was -12.2% (3.6 mg) and -13.0% (6.0 mg), vs -5.4% with placebo; GI events affected 80.9% and 89.7% of participants. Registry: NCT06066515. | subcutaneous |
| Phase 2 obesity dose-finding (Lancet Diabetes Endocrinol 2024): 4.8 mg weekly arm phase 2 trial · 2024 · PMID 38330987 | 387 adults aged 18-75 with BMI 27 or higher, without diabetes | 0.3 mg → 0.6 mg → 0.9 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3.3 mg → 4.2 mg → 4.8 mg once weekly 46 weeks (20-week escalation, 26-week maintenance) Arms were 0.6, 2.4, 3.6 and 4.8 mg weekly. Steps shown are the planned 4.8 mg schedule from the posted results of NCT04667377 (fixed escalation to week 10, flexible from week 11 to 20). Mean weight change at week 46 (planned treatment) was -14.9% with 4.8 mg vs -2.8% with placebo. | subcutaneous |
| Phase 2 MASH (NEJM 2024): 2.4, 4.8 or 6.0 mg weekly for 48 weeks phase 2 trial · 2024 · PMID 38847460 | 293 adults with biopsy-confirmed MASH and fibrosis stage F1-F3 | 6 mg once weekly 48 weeks (24-week rapid escalation, 24-week maintenance) 6.0 mg was the highest arm; all arms started at 0.3 mg (registry NCT04771273). MASH improved without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg) and 43% (6.0 mg), vs 14% with placebo. | subcutaneous |
Sources checked Nov 4, 2026.
Survodutide 10mg in 2 mL
amount to syringe units
| amount | mL | U-100 units | U-40 units |
|---|---|---|---|
| 100 mcg | 0.02 | 2 | 0.8 |
| 250 mcg | 0.05 | 5 | 2 |
| 500 mcg | 0.1 | 10 | 4 |
| 1 mg | 0.2 | 20 | 8 |
| 2 mg | 0.4 | 40 | 16 |
| 2.5 mg | 0.5 | 50 | 20 |
| 5 mg | 1 | 100 | 40 |
One unit on a U-100 syringe is 0.01 mL; on a U-40 it is 0.025 mL.
every Survodutide vial size on sale
reconstitution chart
| vial | 1 mL water | 2 mL water | 3 mL water | 5 mL water |
|---|---|---|---|---|
| 6 mg | 6 mg/mL 10 units = 0.6 mg | 3 mg/mL 10 units = 0.3 mg | 2 mg/mL 10 units = 0.2 mg | 1.2 mg/mL 10 units = 0.12 mg |
| 10 mg | 10 mg/mL 10 units = 1 mg | 5 mg/mL 10 units = 0.5 mg | 3.333 mg/mL 10 units = 0.333 mg | 2 mg/mL 10 units = 0.2 mg |
10 units on a U-100 syringe is 0.1 mL. Every cell is exact arithmetic: amount ÷ water.
what the numbers mean · where they come from
terms and sources
- Label amount or measured amount. The calculator starts from the amount printed on the vial. A lot certificate’s measured content (net peptide content, in mg) can replace it for the vial that was tested. HPLC purity is a share of peak area, not a mass, so a purity-only correction is shown as an estimate. See HPLC, certificate of analysis and how to read a peptide COA.
- Concentration. Amount in the vial ÷ water added. Terms: reconstitution, bacteriostatic water, lyophilized.
- Syringe units. A volume: 0.01 mL per unit on a U-100 syringe, 0.025 mL on U-40. Units say nothing about the compound until the concentration is known.
- Cost per draw. Vial price × amount per draw ÷ vial amount, from the price per mg of a current offer. Offers come from the Survodutide price comparison; certificates from the COA library.
Arithmetic only, on the numbers entered. Amounts from labels or trials are cited references, not recommendations; PeptideTech does not give personal use instructions and does not test products.
short answers
Survodutide calculator questions
How much bacteriostatic water do I add to Survodutide 10mg?
What changes the calculated concentration?
What doses of Survodutide were used in research?
more calculators